MINNEAPOLIS, MN / ACCESSWIRE / February 18, 2016 / BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary technology platform designed to improve the $3.5 billion electrophysiology (EP) marketplace, today announced that the company will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at The Ritz-Carlton in Miami on South Beach February 22, 2016.
The conference will provide companies with a 30-minute time slot to present to an audience of investors and industry professionals. Management will also be available for one-on-one meetings with institutional investors.
During the presentation, Mr. Kenneth Londoner, BioSig Executive Chairman will update the investment community on the Company's recent operational achievements as well as objectives for the next twelve months. To arrange a 1x1 meeting with BioSig Technologies, please contact Mr. Robert Haag of IRTH Communications at bsgm@irthcommunications.com.
Conference registration: complimentary for qualified investors and equity research analysts.
In order to register as an attendee of the conference, please click HERE.
About SeeThruEquity
Since the company's founding in 2011, SeeThruEquity (STE) has been committed to its core mission: providing impactful, high quality research on uncovered and undercovered microcap stocks and hosting investor conferences throughout the year. STE has been able to grow its research universe to over 176 names. STE conferences are the ultimate event for publicly traded companies with less than $1 billion in market capitalization because it augments the conference experience with the firm's research which is part of Wall Street consensus and available across industry leading platforms including Thomson First Call, FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select few. STE has hosted 20 investor conferences which have showcased over 350 companies, attracted over 4500 attendees and have included over 1,700 1-on-1 meetings. For more information, please visit www.steconference.com.
About The Brewer Group
The Brewer Group, Inc. (TBG) is an industry agnostic investment and consulting company with assets ranging numerous sectors. TBG's relationships with key international decision makers spanning government development agencies, financial institutions, multinational corporations, NGOs and numerous leaders in sports and entertainment place TBG in a unique position to grow its portfolio. TBG takes pride in identifying companies whose goal is to make a social impact on the communities in which they serve. For further information, please visit www.thebrewergroup.com.
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3.5 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com ). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets -- areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
Contact:
Investor Relations:
Brian McLaughlin
BioSig Technologies, Inc.
bmclaughlin@biosigtech.com
917-370-9817
or
Robert Haag
Managing Partner
IRTH Communications
BSGM@irthcommunications.com
866-976-4784
SOURCE: BioSig Technologies, Inc.